CompletedNCT01059539
Long-term cariprazine safety and tolerability in bipolarity
About this title
Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder
Read the official source — NCT01059539Researchers studied Cariprazine to find out how it affected manic symptoms in people with bipolarity type I.
Medication studyAges 18–65Multiple countries
Understand this study
What did researchers investigate?
Researchers studied Cariprazine to find out how it affected manic symptoms in people with bipolarity type I.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Springdale and 34 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: February 28, 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 403
- Sponsor
- Forest Laboratories
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Hungary, Poland, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01059539
- Official title
Show the full official title
A Long-term Open-label Study of the Safety and Tolerability of Cariprazine in Patients With Bipolar I Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Springdale, United States · Carson, United States · Cerritos, United States
30 more locations
- Escondido, United States
- Garden Grove, United States
- San Diego, United States
- Santa Ana, United States
- Washington D.C., United States
- Bradenton, United States
- Fort Lauderdale, United States
- Kissimmee, United States
- Rockville, United States
- Flowood, United States
- Creve Coeur, United States
- Saint Charles, United States
- St Louis, United States
- Las Vegas, United States
- Willingboro, United States
- Cincinnati, United States
- Oklahoma City, United States
- Austin, United States
- DeSoto, United States
- Houston, United States
- Gyula, Hungary
- Budapest, Hungary
- Nyíregyháza, Hungary
- Szombathely, Hungary
- Tuszyn, Poland
- Katowice, Poland
- Gdansk, Poland
- Gmina Świecie, Poland
- Gorlice, Poland
- Barcelona, Spain
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers studied Cariprazine to find out how it affected manic symptoms in people with bipolarity type I.
Who is behind this study?
The study sponsor is Forest Laboratories, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Cariprazine.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
"A Randomized, Parallel Group, Open Trial Examining the Safety, Efficacy and Tolerability of Fast Titration, 800mg/day by day 4, of Quetiapine Fumarate Compared to Standard Titration, 400mg/day by ...
Aripiprazole added to divalproex for treatment-resistant bipolar depression